Hebei Senlang Biotechnology Inc., Ltd.
Quick facts
Phase 2 pipeline
- Autologous CD7-targeting CAR T cells · Oncology
Autologous CD7-targeting CAR T cells are engineered patient-derived T cells that recognize and kill CD7-expressing cells, primarily used to target T-cell malignancies. - S1904 CD19 CAR-T
Phase 1 pipeline
- Auto CAR-T
- Autologous BCMA-targeting CAR T cells
- Autologous CAR-T
- Autologous CD19-targeting CAR T cells
- BCMA CAR-T or CD19 CAR-T or CD19×BCMA
- Senl-h19 CAR-T
- Senl-T7
- SENL101
- SENL103
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: